Pharmafile Logo
Pharmafocus logo
Advanced Search
Breo image

GSK and Theravance see FDA nod for asthma indication

March 20, 2015
Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol

An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …

News
michael_r_gallagher_actavis

Actavis gains new Allergan directors

March 20, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Michael Gallagher, Peter McDonnell

Ireland, Dublin-based pharma firm Actavis has added former Allergan members Michael Gallagher and Dr Peter McDonnell to its board of …

Appointment
Sanofi image

Type 1 diabetes market value to double by 2023

March 19, 2015
Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1

The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …

News
Herceptin image

Breast cancer treatment market booming

March 19, 2015
Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb

The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …

News
Daiichi image

AstraZeneca and Daiichi team up for constipation drug

March 19, 2015
Sales and Marketing AstraZeneca, Daiichi, Movantik, constipation, naloxegol, oic

AstraZeneca and Daiichi Sankyo have signed a deal worth around $825 million to jointly commercialise constipation drug Movantik in the …

News
Sanofi image

Sanofi diabetes drug fails to show cardio disease benefit

March 19, 2015
Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes

A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …

News
Teva image

Teva and Ignyta shake hands in oncology deal

March 19, 2015
Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology

Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …

News
paul_wallace

MISSION hires chief business officer from Medivir

March 19, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medvir, mission, paul wallace

UK, Cambridge-based cancer biotech MISSION Therapeutics has appointed Dr Paul Wallace as its chief business officer. Having worked in business …

Appointment
Obama image

Pharma to profit from Obama reforms

March 18, 2015
Sales and Marketing FDA, GlobalData, Obama, US, healthcare, insurance

President Obama’s healthcare reforms will drive massive growth in the US pharma market a new report is predicting. The size …

News
Valeant image

Valeant sprints ahead of Endo to secure Salix

March 18, 2015
Sales and Marketing Actavis, Canada, Endo, Valeant, Xifaxan, methylnaltrexone, rifaximin, salix

Salix Pharmaceuticals has accepted an improved $11.1 billion takeover swoop from Valeant Pharmaceuticals to beat rival bidder Endo International. The …

News
astrazeneca image

AstraZeneca buoyed by late-stage trial success

March 18, 2015
Sales and Marketing AstraZeneca, copd. asthma, formoterol fumarate, glycopyrronium, ptoo3, respiratory

AstraZeneca’s investigational respiratory drug has posted positive results in a Phase III trial in people with COPD, having found it …

News
Survey

The 2015 European Life Sciences Industry Survey on Customer Data

March 18, 2015

Dear Colleague, You are invited to take part in the 2015 European Life Sciences Industry Survey on Customer Data. Your …

Feature
GSK image

GSK premature babies drug starts late-stage trials

March 18, 2015
Sales and Marketing GSK, Retosiban, atosiban, babies, birth, oxytocin, premature

GlaxoSmithKline has initiated Phase III studies to evaluate the safety and efficacy of an investigational treatment for babies born prematurely. …

News
sharon_johnson_catalent

Catalent Pharma Solutions names new unit head

March 18, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing catalent pharma solutions, sharon johnson

UK pharma and healthcare products firm Catalent Pharma Solutions has picked its senior VP Sharon Johnson of the company’s quality …

Appointment

Baxter’s haemophilia drug performs

March 17, 2015
Sales and Marketing BAX 817, VIIa, baxter, haemophilia, rFVIIa

Baxter International has reported positive Phase III clinical trial results for its investigational haemophilia drug BAX 817. The recombinant factor VIIa …

News
Brilinta image

Mixed results for AstraZeneca in high-profile Brilinta study

March 17, 2015
Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor

Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …

News
Jakavi image

Novartis blood cancer drug given EU nod

March 17, 2015
Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib

Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …

News
Sanofi Pasteur image

Sanofi affiliate to supply 37 million vaccines

March 17, 2015
Manufacturing and Production, Sales and Marketing GAVI, Sanofi, Sanofi Pasteur, Shantha Biotechnics, shan5, vaccines

Sanofi’s vaccines division Sanofi Pasteur has confirmed its affiliate Shantha Biotechnics in India has delivered the first 400,000 doses of …

News
Biogen image

Big pharma partners with government over $100m dementia fund

March 17, 2015
Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly

Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …

News
richard_scheller

23andMe assigns chief scientific officer to new unit

March 17, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andm3, Richard Scheller

US personal genetics firm 23andMe has created a new therapeutics group and appointed pharma veteran Richard Scheller as chief science …

Appointment
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026